Go Back Anti AGE-3 Monoclonal Antibody (Clone No.9D8)

Product Detail

The products of the nonenzymatic glycation and oxidation of proteins, lipids and nucleic acids, the advanced glycation end-products (AGEs), accumulate in various pathological conditions, such as diabetes, inflammation, renal failure, and aging. AGEs accumulate at site of microvascular injury in diabetes, including the kidney, the retina, and within the vasculature. The enhanced formation of AGEs also exists in various disease, such as atherosclerosis, Alzheimer’s disease, end-stage renal disease (ESRD), rheumatoid arthritis and liver cirrhosis.

AGEs can arise not only from glucose, but also from dicarbonyl compounds, short chain-reducing sugars and other metabolic pathways of glucose. Among AGEs, glycolaldehyde-derived AGEs (named AGE-3) have diverse toxic biological activities. AGE-3 significantly induces apoptoic cell death, DNA ladder formation and upregulates the secretory forms of VEGF mRNA levels in cultured bovine retinal pericytes. AGE-3 also decreases the viability and suppresses the replication rate in culutered rat Schwann cells, and attenuates cellular insulin sensitivity in 3T3-L1 cells. In human mesenchymal stem cells, AGE-3 increases the apoptotic cell and prevents cognate differentiation into adipose tissue, cartilage, and bone.

This antibody is specific to AGE-3 and will be useful to research for chromic diseases associated with aging and diabetic complications.